<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662649</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2301E1</org_study_id>
    <secondary_id>2007-004122-24</secondary_id>
    <nct_id>NCT00662649</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
  <official_title>An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This extension study of was designed to evaluate the long-term safety, tolerability, and
      efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was
      an extension to the 24-month Core study (CFTY720D2301/NCT00289978).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)</measure>
    <time_frame>Months 0 to end of study (maximum up to 60 months)</time_frame>
    <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free</measure>
    <time_frame>Core baseline to end of study (maximum up to 60 months)</time_frame>
    <description>A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</measure>
    <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
    <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)</measure>
    <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
    <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</measure>
    <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
    <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</measure>
    <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
    <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)</measure>
    <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
    <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)</measure>
    <time_frame>Months 0 to end of study (maximum up to 60 months)</time_frame>
    <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression</measure>
    <time_frame>Core baseline to end of study (maximum up to 60 months)</time_frame>
    <description>Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">920</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-fingolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-fingolimod 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-fingolimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5 mg</intervention_name>
    <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
    <arm_group_label>Placebo-fingolimod</arm_group_label>
    <arm_group_label>Placebo-fingolimod 0.5 mg</arm_group_label>
    <other_name>FTY720</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 1.25 mg</intervention_name>
    <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
    <arm_group_label>Placebo-fingolimod</arm_group_label>
    <arm_group_label>Placebo-fingolimod 1.25 mg</arm_group_label>
    <other_name>FTY720</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should complete the 24 month core study

        Exclusion Criteria:

          -  Patients with other chronic disease of the immune system, malignancies, acute
             pulmonary disease, cardiac failure, etc.

          -  Pregnant or nursing women

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chatswood</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health, Department of Neurology</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Gosford</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Overpelt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sijsele - Damme</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sint-Truiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nepean</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regina</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen - Lochotin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clermont Ferrand Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novaratis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tg. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Rosebank</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Umhlanga</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Cerrahpasa/Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Yenisehir/Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.msclinicaltrials.com</url>
    <description>Fingolimod clinical trials information website</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>June 9, 2012</results_first_submitted>
  <results_first_submitted_qc>June 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2012</results_first_posted>
  <last_update_submitted>June 9, 2012</last_update_submitted>
  <last_update_submitted_qc>June 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis.</keyword>
  <keyword>Relapse-remitting</keyword>
  <keyword>Fingolimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 1272 patients randomly assigned to treatment in the Core study (ClinicalTrials.gov ID NCT00289978), 1033 completed the 24-month double-blind treatment phase and were eligible to enter the Extension study. A total of 920 of the 1033 patients entered the Extension study and received treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
        </group>
        <group group_id="P2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to fingolimod(either 1.25 or 0.5 mg/day) in the Extension study.</description>
        </group>
        <group group_id="P4">
          <title>Placebo-fingolimod 1.25 mg</title>
          <description>Patients randomized to placebo in the core study were re randomized to fingolimod 1.25 mg/day in this extension study.</description>
        </group>
        <group group_id="P5">
          <title>Placebo-fingolimod 0.5</title>
          <description>Patients randomized to placebo in the core study were re randomized to fingolimod 0.5 mg/day in this extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study (24 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="418"/>
                <participants group_id="P4" count="0">This reporting group is used only in extension study.</participants>
                <participants group_id="P5" count="0">This reporting group is used only in extension study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="418"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="369"/>
                <participants group_id="P3" count="332"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study (Month 24 to 60)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="331"/>
                <participants group_id="P3" count="0">This reporting group is used only for core study</participants>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Extension Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="330"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 24</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="331"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 30</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="324"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="136"/>
                <participants group_id="P5" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 36</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="311"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="130"/>
                <participants group_id="P5" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 42</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="301"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 48</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Beginning of Core at Month 54</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245">&quot;completed&quot; refers to patients that completed extension study in different time points.</participants>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
        </group>
        <group group_id="B2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
        </group>
        <group group_id="B3">
          <title>Placebo-fingolimod 1.25 mg</title>
          <description>Patients randomized to placebo in the core study were re randomized to fingolimod 1.25 mg/day in this extension study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo-fingolimod 0.5 mg</title>
          <description>Patients randomized to placebo in the core study were re randomized to fingolimod 0.5 mg/day in this extension study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="289"/>
            <count group_id="B2" value="331"/>
            <count group_id="B3" value="145"/>
            <count group_id="B4" value="155"/>
            <count group_id="B5" value="920"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All demographic measurements are based on extension randomized/safety population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="8.87"/>
                    <measurement group_id="B2" value="36.5" spread="8.60"/>
                    <measurement group_id="B3" value="36.6" spread="9.21"/>
                    <measurement group_id="B4" value="38.1" spread="8.26"/>
                    <measurement group_id="B5" value="37.0" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)</title>
        <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
        <time_frame>Months 0 to end of study (maximum up to 60 months)</time_frame>
        <population>Core Intent to treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod</title>
            <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to FTY720 (either 1.25 or 0.5 mg/day) in the Extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)</title>
          <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
          <population>Core Intent to treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
          <units>Relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" lower_limit="0.138" upper_limit="0.195"/>
                    <measurement group_id="O2" value="0.185" lower_limit="0.158" upper_limit="0.217"/>
                    <measurement group_id="O3" value="0.357" lower_limit="0.310" upper_limit="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
        <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
        <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
        <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug. The analysis included number of patients with evaluable T2 MRI scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod 1.25 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 1.25 mg/day in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-fingolimod 0.5 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 0.5 mg/day in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
          <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
          <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug. The analysis included number of patients with evaluable T2 MRI scans.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Months 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="5.234"/>
                    <measurement group_id="O2" value="2.66" spread="9.395"/>
                    <measurement group_id="O3" value="12.83" spread="17.573"/>
                    <measurement group_id="O4" value="8.12" spread="11.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="4.902"/>
                    <measurement group_id="O2" value="2.58" spread="9.256"/>
                    <measurement group_id="O3" value="2.34" spread="4.745"/>
                    <measurement group_id="O4" value="1.43" spread="2.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Months 0-24 to Months 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="4.393"/>
                    <measurement group_id="O2" value="-0.09" spread="7.423"/>
                    <measurement group_id="O3" value="-10.48" spread="15.980"/>
                    <measurement group_id="O4" value="-6.68" spread="9.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free</title>
        <description>A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.</description>
        <time_frame>Core baseline to end of study (maximum up to 60 months)</time_frame>
        <population>Core Intent to treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod</title>
            <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to FTY720 (either 1.25 or 0.5 mg/day) in the Extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free</title>
          <description>A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.</description>
          <population>Core Intent to treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.85" lower_limit="53.90" upper_limit="65.80"/>
                    <measurement group_id="O2" value="59.29" lower_limit="54.17" upper_limit="64.41"/>
                    <measurement group_id="O3" value="37.18" lower_limit="32.15" upper_limit="42.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
        <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
        <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
        <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug. The analysis included number of patients with evaluable T2 MRI scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod 1.25 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 1.25 mg/day in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-fingolimod 0.5 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 0.5 mg/day in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
          <description>The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
          <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug. The analysis included number of patients with evaluable T2 MRI scans.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Months 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="50.3"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="69.3"/>
                    <measurement group_id="O3" value="52.3"/>
                    <measurement group_id="O4" value="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)</title>
        <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
        <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
        <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod 1.25 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 1.25 mg/day in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-fingolimod 0.5 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 0.5 mg/day in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)</title>
          <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
          <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 to Month 24, n=75, 109, 41, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.011" spread="1.3477"/>
                    <measurement group_id="O2" value="-0.983" spread="1.6291"/>
                    <measurement group_id="O3" value="-1.511" spread="1.6401"/>
                    <measurement group_id="O4" value="-1.419" spread="1.3923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 48, n=75, 109, 41, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.871" spread="1.4164"/>
                    <measurement group_id="O2" value="-0.780" spread="1.9266"/>
                    <measurement group_id="O3" value="-1.103" spread="1.4073"/>
                    <measurement group_id="O4" value="-0.903" spread="1.1406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
        <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
        <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
        <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod 1.25 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 1.25 mg/day in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-fingolimod 0.5 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 0.5 mg/day in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)</title>
          <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
          <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
          <units>Relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Months 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" lower_limit="0.043" upper_limit="0.094"/>
                    <measurement group_id="O2" value="0.111" lower_limit="0.084" upper_limit="0.148"/>
                    <measurement group_id="O3" value="0.301" lower_limit="0.230" upper_limit="0.393"/>
                    <measurement group_id="O4" value="0.292" lower_limit="0.222" upper_limit="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.074" lower_limit="0.051" upper_limit="0.108"/>
                    <measurement group_id="O2" value="0.095" lower_limit="0.070" upper_limit="0.128"/>
                    <measurement group_id="O3" value="0.164" lower_limit="0.117" upper_limit="0.231"/>
                    <measurement group_id="O4" value="0.130" lower_limit="0.092" upper_limit="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)</title>
        <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
        <time_frame>Months 0-24 (core study) and Months 24-48 (extension study)</time_frame>
        <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod 1.25 mg</title>
            <description>Patients randomized to placebo in the Core study were re-randomized to fingolimod 1.25 mg/day in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-fingolimod 0.5 mg</title>
            <description>Patients randomized to placebo in the core study were re-randomized to fingolimod 0.5 mg/day in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)</title>
          <description>ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.</description>
          <population>Extension intent-to-treat (ITT) population: All extension randomized patients that received at least 1 dose of extension study drug.</population>
          <units>Ratio of relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.164" lower_limit="0.830" upper_limit="1.633"/>
                    <measurement group_id="O2" value="0.850" lower_limit="0.658" upper_limit="1.099"/>
                    <measurement group_id="O3" value="0.547" lower_limit="0.390" upper_limit="0.767"/>
                    <measurement group_id="O4" value="0.446" lower_limit="0.320" upper_limit="0.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)</title>
        <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
        <time_frame>Months 0 to end of study (maximum up to 60 months)</time_frame>
        <population>Core intent-to-treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug. This analysis included only patients with value at both core baseline and end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod</title>
            <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to fingolimod (either 1.25 or 0.5 mg/day) in the Extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)</title>
          <description>Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.</description>
          <population>Core intent-to-treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug. This analysis included only patients with value at both core baseline and end of study.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.639" spread="1.9265"/>
                    <measurement group_id="O2" value="-1.674" spread="2.1182"/>
                    <measurement group_id="O3" value="-2.241" spread="2.1873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression</title>
        <description>Kurtzke’s Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.</description>
        <time_frame>Core baseline to end of study (maximum up to 60 months)</time_frame>
        <population>Core intent-to-treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 1.25 mg/day, in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients continued the same dose to which they had been randomized in the core study, fingolimod 0.5 mg/day, in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-fingolimod</title>
            <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to fingolimod(either 1.25 or 0.5 mg/day) in the Extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression</title>
          <description>Kurtzke’s Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.</description>
          <population>Core intent-to-treat (ITT) population: All patients who were randomized in the Core study and received at least 1 dose of Core study drug.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.15" lower_limit="69.54" upper_limit="78.75"/>
                    <measurement group_id="O2" value="73.90" lower_limit="69.44" upper_limit="78.37"/>
                    <measurement group_id="O3" value="66.28" lower_limit="61.28" upper_limit="71.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety reported on extension safety population which includes all patients who received at least 1 dose of Extension study drug. Patients were analyzed according to the actual treatment received during extension.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fingolimod 1.25mg</title>
          <description>Patients randomized to fingolimod 1.25 mg/day in the Core study. These patients continued the same dose in the Extension study.</description>
        </group>
        <group group_id="E2">
          <title>Fingolimod 0.5mg</title>
          <description>Patients randomized to fingolimod 0.5 mg/day in the Core study. These patients continued the same dose in the Extension study.</description>
        </group>
        <group group_id="E3">
          <title>Placebo-Fingolimod 1.25mg</title>
          <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to fingolimod 1.25 mg/day in the Extension study.</description>
        </group>
        <group group_id="E4">
          <title>Placebo-Fingolimod 0.5mg</title>
          <description>Patients randomized to placebo in the Core study who were subsequently re-randomized to fingolimod 0.5 mg/day in the Extension study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphomatoid papulosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Parapsoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Selective abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="130" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

